[1] Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res, 2007, 67(13): 6130–6135. <\p>

[2] Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene, 2008, 27(12): 1788–1793. <\p>

[3] Michael MZ, SM OC, Van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res, 2003, 1(12): 882–891. <\p>

[4] Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology, 2009, 77(1): 12–21. <\p>

[5] Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep, 2006, 16(4): 845–850. <\p>

[6] Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Mat-subara H. miR-145, miR-133a and miR-133b: Tu-mor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer, 2010, 127(12): 2804–2814. <\p>

[7] Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Morenó I, Monzo M, García-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer, 2006, 5: 29. <\p>

[8] Chiyomaru T, Tatarano S, Kawakami K, Enokida H, Yo-shino H, Nohata N, Fuse M, Seki N, Nakagawa M. SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer. Prostate, 2011, 71(14), doi: 10.1002/pros.21372. <\p>

[9] Chen H, Toyooka S, Gazdar AF, Hsieh JT. Epigenetic reg-ulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem, 2003, 278(5): 3121–3130. <\p>

[10] Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF, Shi-mizu N. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res, 2004, 10(6): 2082–2089. <\p>

[11] Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, Naito M, Toyota M, Gazdar AF, Shimizu N. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer, 2005, 92(6): 1117–1125. <\p>

[12] Yano M, Toyooka S, Tsukuda K, Dote H, Ouchida M, Ha-nabata T, Aoe M, Date H, Gazdar AF, Shimizu N. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer, 2005, 113(1): 59–66. <\p>

[13] Prunier C, Howe PH. Disabled-2 (Dab2) is required for transforming growth factor β-induced epithelial to me-senchymal transition (EMT). J Biol Chem, 2005, 280(17): 17540–17548. <\p>

[14] Jechlinger M, Grunert S, Tamir IH, Janda E, Lüdemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N. Expression profiling of epithelial plasticity in tumor progression. Oncogene, 2003, 22(46): 7155–7169. <\p>

[15] Strizzi L, Bianco C, Normanno N, Seno M, Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun YP, Sanicola M, Salomon DS. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol, 2004, 201(2): 266–276. <\p>

[16] Yang JL, Du XL. Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy. Surg Oncol, 2013, 22(3): e53–e57. <\p>

[17] Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, Wang TH, Lai CH. Regulation of ovarian cancer progression by microRNA- 187 through ta